SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

InvestoGain Australia

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A BCDE FGHIJ KLMN OPQR STUV WXYZ

Browse current Australian managed funds

0-9A BCDE FGH IJKL MNOP QRST UVWX YZ

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

G MEDICAL INNOVATIONS HOLDINGS LIMITED (GMV)

Listed on ASX

SHARE PRICES

(updated weekly)

Former (or subsequent) names

 

Shareholder links

Our website ranking of GMV: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Registry Services Level 5 126 Phillip Street Sydney NSW 2000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

Address: c/o G Medical Diagnostic Services, Inc. 1500 Lakeside Dr. Ste 115 Bannockburn, IL 60015 USA
Tel:  +1 345 749 2000 Fax: 

Date first listed: 10/05/2017
Company Secretary: Brett Tucker
Sector: Health Care Equipment & Services Industry Group: 
Activities: mHealth and e-health solutions The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories

The securities of G Medical Innovations Holdings Ltd will be reinstated to Official Quotation as from the commencement of trading on Wednesday, 8 April 2020 following lodgement of its Annual Report for the year(s) ended 31 December 2019.

07/04/2020

The company releases a notice of Proposed issue of Securities - GMV.

07/04/2020

The company has entered into a deed of variation to extend the repayment date of the settlement sum owing to MEF I,L.P. under the deed of termination, settlement and release to 30 April 2020. The company has also agreed to issue to Magna on or before 30 April 2020 such number of fully paid ordinary shares in the company equivalent to US$260,000. The settlement sum owing and payable to Magna will be reduced by US$130,000 and, as at the date of this announcement, the company will repay to Magna an amount of US$3,260,665 by 30 April 2020 in full and final settlement of the company's outstanding debt to Magna.

07/04/2020

The company releases an Appendix 4G.

07/04/2020

The company lodges its Annual Report.

07/04/2020

Prizma now licensed for use in Taiwan by Taiwan Food and Drug Administration. Prizma device can detect and monitor symptoms associated with infection and acute and chronic illness. Significant achievement allows GMV to progress Taiwan market entry. Commercial negotiations are ongoing G Medical's existing in country partners.

06/04/2020

Prizma now registered on Italian Health Ministry Database of medical products. Prizma device can detect and monitor symptoms associated with infection and acute and chronic illness "“ device has the potential to alleviate pressure on hospitals and clinics. First Prizma units ordered and purchased by Meditel in expedited market initiative. GMV and Meditel confident of significant uptake as demand for telehealth and e-health technologies and services increases.

06/04/2020

G Medical is currently experiencing business disruptions due to the national emergency in Israel, as well as broader shutdowns in the United States, China and Australia as a result of the COVID-19 pandemic. These interruptions have left G Medical unable to compile and finalise the relevant documentation required for its 2019 annual report. G Medical is working with internal parties and BDO to finalise its financial report and lodge them as soon as possible.

31/03/2020

The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of an announcement regarding an update on the registration status of GMV's products and the lodgement of its audited annual report for the year ended 31 December 2019.

31/03/2020

The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted immediately, following the release by GMV of an announcement regarding a funding facility.

04/12/2019

A$30m funding facility secured to significantly fast track US and global sales growth of its market leading Prizma and VSMS patch. GMV to capitalise on immediate growth opportunities and expand US sales force 4-fold. Funding secured from top tier financial institution GEM Global and can be drawn at GMV's discretion. Product suite gaining significant traction with multiple opportunities developing in USA and other markets. Considerable near-term value drivers expected from end of H1 2020 and going forward. GEM's decision to fund GMV is a vote of confidence to the future growth of the company.

04/12/2019

The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of an announcement regarding a funding facility.

29/11/2019

The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted from the commencement of trading on Tuesday, 22 October 2019, following the receipt of a response to an ASX Query.

22/10/2019

The company issues a response to ASX Query.

22/10/2019

The company issues a response to ASX Query.

09/10/2019

The company is in the process of preparing a response to an ASX query and will provide further updates at the appropriate time.

02/10/2019

ASX has suspended the securities of G Medical Innovations Holdings Limited from official quotation pursuant to Listing Rule 17.3, for failure to respond to an ASX query. The suspension will continue until the Company provides a satisfactory response to ASX's query.

17/09/2019

The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the response to an ASX query letter.

10/09/2019

The securities of G Medical Innovations Holdings Limited will be reinstated to Official Quotation as from the commencement of trading on Tuesday, 5 March 2019 following lodgement of its Appendix 4E Preliminary Final Report for the year(s) ended 31 December 2018.

04/03/2019

The company releases an Appendix 4G.

04/03/2019

The company lodges its Appendix 4E and Annual Financial Statements.

04/03/2019

The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of the Company's preliminary final report.

28/02/2019

The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted immediately following receipt of an announcement.

10/11/2017

The company has executed a binding memorandum of understanding between its subsidiary, G Medical Innovations Asia Limited and First Channel for the distribution of G Medical's products and services in India and Taiwan.

10/11/2017

The securities of G Medical Innovations Holdings Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement.

08/11/2017

listed entity carried for record purposes only

10/05/2017

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    22/05/2020Yacov Geva-47,125,000$0.075$3,534,375
    03/06/2019Yacov Geva742,168$0.246$182,566
    03/04/2018Yacov Geva1,036,000$0.274$283,876
    13/02/2018Ashley Krongold250,000$0.302$75,468
    07/02/2018Yacov Geva1,470,000$0.299$438,772

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Kenneth MelaniChairman10/05/2017
    Yacov GevaManaging Director, CEO10/05/2017
    Zeev RotsteinNon Exec Director05/03/2019
    Brendan de KauweDirector10/05/2017
    Urs WettsteinDirector10/05/2017
    Shuki GleitmanDirector10/05/2017

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Sam SkontosNon Exec Director10/05/201708/04/2019
    Louis AntoniouDirector10/05/201703/03/2019
    Ashley KrongoldNon Exec Director19/09/201724/04/2018

    Date of first appointment, title may have changed.